FAQ: What Employers and Employees Should Know About GLP 1 Coverage, Costs and Access

Glucagon-like peptide-1 (GLP‑1) medications are changing how obesity and type 2 diabetes are treated, offering significant weight loss and health benefits. Widely used drugs include Wegovy (semaglutide), Ozempic (semaglutide injection), Rybelsus (semaglutide tablets) and Mounjaro (tirzepatide). While these therapies can improve health outcomes, they have also become a major driver of prescription costs for employers. A recent Navitus Health Solutions survey found that 68% of GLP‑1 users said cost influenced their decision to start or continue treatment, highlighting how affordability affects both employees and employer benefit planning. This FAQ addresses what employers and employees need to know about coverage, costs and access.

1. Why are GLP‑1 drugs becoming a major cost driver for employers?

GLP-1 medications have become a significant part of prescription spending for employers, according to Nick Conway, president of Rx Solutions at NFP.

“GLP‑1s have effectively created a third pillar of pharmacy spend and most employers don't yet have a mature playbook to manage it,” Conway said, adding that over half of employers now cite GLP‑1s as a top driver of rising drug costs while employee satisfaction with cost sharing has declined.

2. How should employers manage costs while responding to employee demand for GLP‑1 coverage?

Employers can’t just remove coverage without affecting morale or retention, according to Conway. He suggested that organizations use strategies such tightening prior authorization, reinforcing step therapy and explore outcomes‑based contracting to manage use while maintaining access, if they aren’t already.

“Nearly a third of employees say GLP‑1 coverage could influence employment decisions,” he said.

Companies offering coverage may gain an edge in recruiting and keeping employees, while balancing costs with structured frameworks that capture long‑term value.

The Navitus survey also revealed that more than 70% of survey respondents said they support requirements such as prior authorization, BMI thresholds or participation in wellness programs before gaining GLP-1 coverage. This suggests many patients understand the need for structured benefit rules.

3. What should employers know about FDA‑approved versus compounded or direct‑to‑consumer GLP‑1 drugs?

Not all GLP‑1 medications are the same, expressed William Soliman, M.D., former pharma executive and founder and CEO of the Accreditation Council for Medical Affairs (ACMA). FDA‑approved drugs such as Wegovy, Ozempic and Mounjaro go through rigorous testing for safety and effectiveness, with standardized manufacturing and labeling. Compounded or direct‑to‑consumer versions don’t go through the same review process and could cause dosing errors or safety issues.

“If you’re a patient, ask yourself: is this the FDA‑approved branded product in manufacturer packaging, or a compounded vial? If compounded: why is compounding medically necessary for this specific patient and how is the dosing verified,” Soliman said. “The bottom line is that FDA-approved GLP-1s are standardized products with known dosing and labeling.”

The Navitus survey also found that nearly 60% of users are aware of safety concerns tied to compounded GLP-1 products. More than 86% said they would be willing to pay more for an FDA-approved medication.

4. How do high deductibles or out‑of‑pocket purchases affect safety and long‑term outcomes?

When people face high costs before insurance starts paying, research shows they are less likely to consistently take long‑term medications. One study found that enrollment in high‑deductible health plans was associated with a 5% drop in adherence to medications for cardiovascular risk factors, revealing that higher cost‑sharing can reduce proper use of important treatments.

Soliman noted that cash‑pay routes and stop‑and‑start therapy driven by cost can raise the risk of dosing errors and make long‑term use less effective, increasing the likelihood of side effects.

Additionally, out of the 2,000 GLP-1 users part of the Navitus survey, 24% said they pay more than $250 per prescription fill, and nearly 8% pay $500 or more. Among those who stopped taking the medication, cost was the most common reason, even more than side effects or reaching a weight goal.

5. What is the emerging potential for GLP‑1 drugs beyond diabetes and weight loss, and how could this affect employer benefits?

GLP‑1 receptors are not only involved in appetite regulation but also in brain circuits tied to reward and reinforcement, Soliman shared. Early clinical research suggests potential for treating conditions such as alcohol and nicotine use disorders, though these uses are still investigational and off‑label, he added. It’s critical that patients not start GLP‑1 treatment for addiction without physician supervision.

Conway added that if GLP‑1 therapies gain FDA approval for new indications such as addiction, employers may have to rethink how pharmacy, medical and behavioral health benefits work together.

“Employers that get ahead of this will have successfully built cross‑benefit analytics and unified care navigation to meet future needs,” he said.

6. How do GLP‑1 therapies impact overall health outcomes beyond weight loss?

Many patients experience broader health benefits beyond weight management, including improvements in blood sugar and blood pressure. These effects can reduce other healthcare costs and influence employee productivity and well-being. For employers, these health benefits make coverage decisions more complex but potentially more valuable.

Wegovy was also FDA-approved to reduce the risk of major cardiovascular events—including heart attack, stroke and cardiovascular death—in adults with cardiovascular disease and obesity or overweight. The approval was based on a large outcomes trial that showed a significant reduction in these serious events compared with placebo, demonstrating that GLP‑1 drugs can improve long‑term health outcomes beyond weight loss alone.

These effects are separate from investigational uses in addiction treatment.

7. What are the latest GLP‑1 developments, and what should employers watch for?

February 2026 updates:

1. Novo Nordisk’s REDEFINE 4 trial: CagriSema (cagrilintide/semaglutide) showed significant weight loss in obesity but did not meet its primary endpoint versus Eli Lilly’s tirzepatide. Higher‑dose studies are planned.
2. Price reduction: Novo Nordisk announced a lower U.S. list price of $675 per month for Wegovy, Ozempic and Rybelsus starting January 1, 2027, which may improve access for patients with high out‑of‑pocket costs.
3. Oral GLP‑1s: The FDA approved the first daily Wegovy pill—a once‑daily oral GLP‑1 therapy that showed a roughly 16.6 % average weight loss in the 64‑week OASIS 4 trial—and it is expected to be available early 2026 for adults with obesity or overweight.
4. Pipeline: Next‑generation therapies such as retatrutide, which targets GLP‑1, GIP and glucagon pathways, are in late‑stage development and could deliver even greater weight‑loss effects if approved.

Conway and Soliman shared a common agreement that employers should track these developments closely, as they could influence coverage decisions, pharmacy budgets and employee access in the coming years.

This FAQ was approved for accuracy and for publishing by Conway and Soliman.